CJC-1295 with DAC
A long-acting synthetic analogue of GHRH with Drug Affinity Complex for extended half-life.
Research Use Only. This product is intended for laboratory research purposes only and is not for human consumption. Not for sale to minors.
Product Description
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of CJC-1295 that incorporates a lysine linker to enable binding to albumin in the bloodstream. This modification extends the half-life to approximately 6–8 days compared to the shorter-acting version. Research has investigated its sustained GH-releasing properties.
Research Information
Research on CJC-1295 DAC has demonstrated prolonged elevation of GH and IGF-1 levels compared to non-DAC formulations. Studies have investigated its effects on body composition, bone density, and metabolic function. The extended half-life allows for less frequent administration in research protocols.
Dosage Guidance
Research protocols typically use 1–2 mg administered once or twice weekly. Standard vials contain 2mg lyophilized powder. All dosing information is for research reference only.